tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

KPTI Stock Latest News

Michael Mason Resigns as CFO of Karyopharm Therapeutics
Company AnnouncementsMichael Mason Resigns as CFO of Karyopharm Therapeutics
23d ago
8K
KPTI
Karyopharm price target lowered to $5 from $8 at Baird
PremiumThe Fly
Karyopharm price target lowered to $5 from $8 at Baird
1M ago
KPTI
Karyopharm narrows 2024 revenue view to $145M-$160M from $140M-$160M
PremiumThe Fly
Karyopharm narrows 2024 revenue view to $145M-$160M from $140M-$160M
2M ago
KPTI
Karyopharm reports Q2 EPS (20c), consensus (30c)
PremiumThe Fly
Karyopharm reports Q2 EPS (20c), consensus (30c)
2M ago
KPTI
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
PremiumPress Releases
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
2M ago
KPTI
Karyopharm Therapeutics INC (KPTI) Q2 Earnings Cheat Sheet
PremiumPre-EarningsKaryopharm Therapeutics INC (KPTI) Q2 Earnings Cheat Sheet
2M ago
KPTI
Karyopharm granted FDA orphan designation in Ewing sarcoma
Premium
The Fly
Karyopharm granted FDA orphan designation in Ewing sarcoma
2M ago
KPTI
Karyopharm’s padnarsertib granted FDA orphan designation in sarcoma treatment
Premium
The Fly
Karyopharm’s padnarsertib granted FDA orphan designation in sarcoma treatment
2M ago
KPTI
Karyopharm price target lowered to $7 from $8 at H.C. Wainwright
PremiumThe Fly
Karyopharm price target lowered to $7 from $8 at H.C. Wainwright
3M ago
KPTI
Karyopharm presents updated exploratory subgroup analyses from SIENDO study
PremiumThe Fly
Karyopharm presents updated exploratory subgroup analyses from SIENDO study
4M ago
KPTI
Karyopharm Shareholders Back Expansion and Elect Directors
PremiumCompany Announcements
Karyopharm Shareholders Back Expansion and Elect Directors
4M ago
8K
KPTI
Karyopharm files to sell 45.78M shares of common stock for holders
PremiumThe Fly
Karyopharm files to sell 45.78M shares of common stock for holders
4M ago
KPTI
Karyopharm Therapeutics Enhances Financial Stability and Liquidity
PremiumCompany AnnouncementsKaryopharm Therapeutics Enhances Financial Stability and Liquidity
5M ago
8K
KPTI
Karyopharm still sees 2024 revenue $140M-$160M, consensus $146.52M
Premium
The Fly
Karyopharm still sees 2024 revenue $140M-$160M, consensus $146.52M
5M ago
KPTI
Karyopharm reports Q1 EPS (32c), consensus (33c)
Premium
The Fly
Karyopharm reports Q1 EPS (32c), consensus (33c)
5M ago
KPTI
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
PremiumPress Releases
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
5M ago
KPTI
Is KPTI a Buy, Before Earnings?
PremiumPre-Earnings
Is KPTI a Buy, Before Earnings?
5M ago
KPTI
Karyopharm price target lowered to $8 from $10 at H.C. Wainwright
PremiumThe Fly
Karyopharm price target lowered to $8 from $10 at H.C. Wainwright
7M ago
KPTI
Bad News for Karyopharm Therapeutics INC Stock: This New Risk Has Been Added
PremiumCompany Announcements
Bad News for Karyopharm Therapeutics INC Stock: This New Risk Has Been Added
7M ago
KPTI
Karyopharm sees 2024 revenue $140M-$160M, consensus $152.02M
PremiumThe FlyKaryopharm sees 2024 revenue $140M-$160M, consensus $152.02M
7M ago
KPTI
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Premium
Press Releases
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
7M ago
KPTI
Karyopharm reports Q4 EPS (36c), consensus (31c)
Premium
The Fly
Karyopharm reports Q4 EPS (36c), consensus (31c)
7M ago
KPTI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >